Post-Neoadjuvant Treatment MRI Based AI System to Predict pCR for Rectal Cancer

Condition:   Rectal Cancer Interventions:   Procedure: the artificial intelligence;   Procedure: the radiologists Sponsors:   Sixth Affiliated Hospital, Sun Yat-sen University;   Sir Run Run Shaw Hospital;   The Third Affiliated Hospital of Kunming Medical College. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Huang Y, Gu X, Ge K, Fu G, Chu J, Wei W Abstract Neoadjuvant chemoradiotherapy has been established as the standard treatment for patients with locally advanced rectal cancer. However, the role of radiotherapy (RT) has not been fully confirmed in advanced colon cancer (LACC). We postulated that patients with pathological T4N2 locally advanced colon cancer would benefit more from RT. 6715 pT4N2M0 colon cancer patients were included in the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoints were 5-year overall survival (OS) and cancer-specific survival (CSS). Propensity score m...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Condition:   Rectum Cancer Intervention:   Procedure: 'Watch and Wait' Approach or Organ Preservation Sponsor:   Beijing Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ew D. Beggs Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting targets along this pathway, in enhancing radiotherapy response. We identified several studies using in vitro cancer cell lines, in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Huang CM, Huang CW, Ma CJ, Yeh YS, Su WC, Chang TK, Tsai HL, Juo SH, Huang MY, Wang JY Abstract We aimed to identify predictors of a pathological complete response (pCR) in patients with locally advanced rectal cancer (LARC) following a multimodality therapy. We retrospectively reviewed 236 patients with LARC treated with neoadjuvant chemoradiotherapy (CRT) followed by radical resection from January 2011 to December 2017. Patients were administered CRT, which comprised radiotherapy and chemotherapy with an oxaliplatin plus 5-fluorouracil- or fluoropyrimidine-based regimen. Clinical factors were correlated ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
ConclusionThe addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients provides comparable efficacy and acceptable safety. However, the results should be interpreted cautiously due to the small amount of relevant data and need further confirmation by more future studies.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 29 April 2020Source: European Journal of Surgical OncologyAuthor(s): Laura Lorenzon, Karol Polom
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
To report the long-term outcomes of neoadjuvant altered fractionation short-course radiotherapy in 271 consecutive patients with stage II-III rectal cancer.
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
ConclusionsMRI T2-weighted sequences-based TA was not effective in predicting pathological complete response to nCRT in patients with LARC. Further studies are needed to thoroughly investigate the potential of MRI TA in this setting.
Source: La Radiologia Medica - Category: Radiology Source Type: research
Abstract BACKGROUND/AIM: A great proportion of patients with rectal cancer initially present with locally advanced disease and can potentially benefit from neoadjuvant concurrent chemoradiotherapy (CCRT) for downstaging before surgery. However, risk and clinical outcome stratification remain a great challenge. We aimed to find the potential biomarker to predict the effect of neoadjuvant CCRT on rectal cancer. METHODS: We identified epiregulin (EREG) as the most significant predictive marker for neoadjuvant CCRT response from the published rectal cancer transcriptome data set GSE35452. We collected 172 biopsy ...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
AbstractBackgroundMargin negative resection of rectal cancer with minimally invasive techniques remains technically challenging. Robotic surgery has potential advantages over traditional laparoscopy. We hypothesize that the difference in the rate of negative margin status will be  
Source: Surgical Endoscopy - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | Neoadjuvant Therapy | Radiology | Rectal Cancers | Research